Citation Impact
Citing Papers
Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology.
2002
Toxicity, mechanism and health effects of some heavy metals
2014 Standout
Reactive Oxygen Species and the Central Nervous System
1992 Standout
Hydrogen-Bond Patterns of Dialkylpyridone Iron Chelators and Their 1:1 Formic Acid Solvates: Description, Prediction, and Role in Crystal Packing
1993
Potentiation of iron accumulation in cardiac myocytes during the treatment of iron overload in gerbils with the hydroxypyridinone iron chelator CP94
1994
Academic Freedom in Clinical Research
2002
Critical Comparison of Novel and Existing Methods of Compliance Assessment During a Clinical Trial of an Oral Iron Chelator
1994
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
2009 Standout
Aluminium toxicity: its relationship with bone and iron metabolism
1996
Nutritional immunity: transition metals at the pathogen–host interface
2012 Standout
The β-Thalassemias
1999 Standout
Advances in metal-induced oxidative stress and human disease
2011 Standout
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
2013 Standout
Role of ‘catalytic’ iron in an animal model of minimal change nephrotic syndrome
1996
Non-compliance—or how many aunts has Matilda?
1993 Standout
Antiproliferative and Apoptotic Effects of Iron Chelators on Human Cervical Carcinoma Cells
2002
Liver iron depletion and toxicity of the iron chelator Deferiprone (L, CP20) in the guinea pig
1997
Deferiprone protects against doxorubicin-induced myocyte cytotoxicity
2002
A systematic review of the associations between dose regimens and medication compliance
2001 Standout
Measuring reactive species and oxidative damagein vivoand in cell culture: how should you do it and what do the results mean?
2004 Standout
Pyridoxal Isonicotinoyl hydrazone and its analogues
2002
Heme Oxygenase-1/Carbon Monoxide: From Basic Science to Therapeutic Applications
2006 Standout
Design of iron chelators with therapeutic application
2012
Selective capture of cesium and thallium from natural waters and simulated wastes with copper ferrocyanide functionalized mesoporous silica
2010 Standout
Strategies of antioxidant defense
1993 Standout
Iron Chelators for Thalassaemia
1998
Patient adherence to treatment: three decades of research. A comprehensive review
2001 Standout
A Risk-Benefit Assessment of Iron-Chelation Therapy
1997
Stroke in Children With Sickle Cell Anaemia
2001
Protection against tissue damage in vivo by desferrioxamine: What is its mechanism of action?
1989
Oxidative mechanisms in the toxicity of metal ions
1995 Standout
Drug glucuronidation in humans
1991
Global epidemiology of haemoglobin disorders and derived service indicators
2008 Standout
5 Thalassaemia: clinical management
1998
Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia Major
1995
The ferritins: molecular properties, iron storage function and cellular regulation
1996 Standout
Reductive release of ferritin iron: A kinetic assay
1988
Chemistry and biology of siderophores
2010 Standout
Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron
2009 Standout
Role of antioxidants in paraquat toxicity
2002 Standout
Long-Term Safety and Effectiveness of Iron-Chelation Therapy with Deferiprone for Thalassemia Major
1998
Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species
1993 StandoutScience
Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin
2006
Moyamoya Disease and Moyamoya Syndrome
2009 Standout
Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness
1999 Standout
2 Clinically Useful Chelators of Tripositive Elements
1991
Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: Comparison of their mechanism of protection with that of desferrioxamine
1992
Iron-Chelating Therapy
1988
Cell Biology of the Glomerular Podocyte
2003 Standout
Free radicals, antioxidants, and human disease: where are we now?
1992 Standout
Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences
2006
Heavy metal induced oxidative stress & its possible reversal by chelation therapy.
2008 Standout
Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents
1995 StandoutNobel
[1] Role of free radicals and catalytic metal ions in human disease: An overview
1990 Standout
Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo
1995
Incorporation of Hydroxypyridinone Ligands into Self-Assembled Monolayers on Mesoporous Supports for Selective Actinide Sequestration
2004
Patterns in Hydrogen Bonding: Functionality and Graph Set Analysis in Crystals
1995 Standout
Human UDP-Glucuronosyltransferases: Metabolism, Expression, and Disease
2000 Standout
Vanadium (IV) and vanadium (V) complexes of deferoxamine B in aqueous solution
1995
Principles and Recent Developments in Chelation Treatment of Metal Intoxication
1999
The Chemistry and Biochemistry of Vanadium and the Biological Activities Exerted by Vanadium Compounds
2004 Standout
Role of deferiprone in chelation therapy for transfusional iron overload
2003
Rational Design of Sequestering Agents for Plutonium and Other Actinides
2003
Interpretation of europium(III) spectra
2015 Standout
Compliance assessed by the Medication Event Monitoring System.
1991
Magnetic Nanoparticles: Design and Characterization, Toxicity and Biocompatibility, Pharmaceutical and Biomedical Applications
2012 Standout
Iron-Chelating Therapy and the Treatment of Thalassemia
1997
Comparative Study of Antioxidant Properties and Total Phenolic Content of 30 Plant Extracts of Industrial Interest Using DPPH, ABTS, FRAP, SOD, and ORAC Assays
2009 Standout
2 The development of iron chelating drugs
1989
Long-Term Trial of Deferiprone in 51 Transfusion-Dependent Iron Overloaded Patients
1998
Works of L Sheppard being referenced
Selection of a new generation of orally active α‐ketohydroxypyridine iron chelators intended for use in the treatment of iron overload
1993
Differential toxicity of α‐keto hydroxypyridine iron chelators and desferrioxamine to human haemopoietic precursors in vitro
1994
Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one
1990
Long‐term trial with the oral iron chelator 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one (L1) I. IRON CHELATION AND METABOLIC STUDIES
1990
Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload
1995
Comparative iron binding studies of bis- and tris(3-hydroxy-2-methylpyrid-4-ones) and desferrioxamine
1991
Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.
1987
Synthetic methods and in vitro iron binding studies of the novel 1-alkyl-2-ethyl-3-hydroxypyrid-4-one iron chelators
1988
Simple synthesis of the potent iron chelators 1-alkyl-3-hydroxy-2-methylpyrid-4-ones
1987
Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
1987
1,2-DIMETHYL-3-HYDROXYPYRID-4-ONE, AN ORALLY ACTIVE CHELATOR FOR TREATMENT OF IRON OVERLOAD
1987